Is aflibercept an optimal treatment for wt RAS mCRC patients after progression to first line containing anti-EGFR?
Ruth VeraElena MataEncarna GonzálezIgnacio JuezVicente AlonsoPatricia IranzoNieves P MartínezCarlos LópezJosé M CabreraMaría J SafontAna Ruiz-CasadoMercedes SalgadoBeatriz GonzálezPilar EscuderoFernando RiveraCarles PericayPublished in: International journal of colorectal disease (2020)
The results show that patients with wt RAS mCRC who received an anti-EGFR as part of the first-line treatment achieved similar RR, PFS, OS, and toxicities to those reported in VELOUR trial. These results suggest that FOLFIRI-aflibercept after first-line treatment with anti-EGFR is an appropriated option for RAS wt mCRC.